Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study established a stable cell line for CRF1 receptor screening, which can be used to develop functional cosmetics and modulators potentially affecting hair re-growth.

This article describes the development and validation of a standardized instrument for measuring skin involvement in cutaneous lupus erythematosus, aiming to aid future clinical research and trials.

This double-blinded randomized clinical trial found that combining topical vitamin D analog (calcipotriol) and intra-lesion PRP led to a greater reduction in hair loss severity in alopecia areata patients compared to either treatment alone, with significant improvements observed across all groups.

A new acne cream effectively reduced acne in trials and awaits FDA approval.

This review assessed randomised clinical trials on the efficacy and safety of topical and systemic JAK inhibitors for alopecia areata, finding significant hair coverage improvement with ritlecitinibe and baricitinibe, though prolonged treatment is often needed to maintain results.

This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.

This systematic review reports promising efficacy and safety of Tofacitinib for treating Alopecia Areata in children, though further randomized studies are needed due to the low quality of existing evidence.

This study found that treatment with oral tofacitinib, alone or with other therapies, was associated with clinical improvement in most patients with recalcitrant lichen planopilaris.

In a real-world study, baricitinib was effective for scalp, eyebrow, and eyelash regrowth in patients with alopecia areata, showing clinically meaningful improvements as early as 3 months and increasing up to 12 months; satisfaction and perceived improvement were also high among participants.

This paper reviews the diverse skin, nail, and hair changes caused by medications, highlighting hyperpigmentation, alopecia, and nail structural alterations, but reports no new data.

This study documented successful use of Brevilin-A, a topical treatment, in pediatric patients with alopecia areata, indicating it as a potentially safe and effective option for managing mild-moderate cases and resistant forms of the disease.

This study observed that a tacrolimus solution (0.1%) applied to the scalp was effective and well-tolerated for treating inflammatory scalp conditions, with 72.7% of patients showing an excellent response after 2 months of treatment, which persisted after 6 months.

This article reviews autologous cell therapy for facial wrinkles, detailing the use of LaViv and its adverse events, but reports no new clinical results.

In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.

In this study, upadacitinib was reported as effective in rapidly treating psoriasiform eczema in five male patients and showed varying degrees of effectiveness on other immune-mediated comorbidities like alopecia areata, vitiligo, ulcerative colitis, and hidradenitis suppurativa.

Reflectance confocal microscopy helped diagnose and manage a woman's hair loss without needing a biopsy.

This article discusses the use of a high-magnification digital video microscope for diagnosing and treating androgenetic alopecia and reports no new clinical results.

In a randomized controlled trial, King et al. found that oral baricitinib at doses of 2 mg and 4 mg significantly improved hair regrowth in adults with alopecia areata compared to placebo, supporting its efficacy and safety for those with substantial scalp hair loss.

In this study, oral acitretin therapy for psoriasis was associated with excess granulation tissue in the nail sulcus and noncicatricial universal alopecia.

Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.

In this observational study, AC5 reduced hair loss in 89% of subjects with mild androgenic alopecia, and was well tolerated and appreciated by most participants.

This study reviewed evidence suggesting that systemic corticosteroids, particularly in pulse regimens like dexamethasone and betamethasone oral mini-pulse, effectively slow vitiligo progression and support repigmentation, while offering a favorable safety profile compared to continuous therapy.

In this study, combining baricitinib and prednisone effectively achieved complete hair regrowth in seven out of eight women with very severe alopecia areata, contrasting with less effective results from each drug used alone.

Infliximab was effective in treating a scalp condition that did not respond to other treatments.

This review summarizes existing literature on hydroxychloroquine for treating autoimmune-related hair disorders, highlighting its variable efficacy and emphasizing the need for individualized treatment decisions, but reports no new clinical results.

In this case study, the combination therapy of isotretinoin and rifampicin was reported to effectively improve symptoms in a 58-year-old female patient with folliculitis decalvans, suggesting this approach may warrant further investigation for treating this challenging condition.

This case report suggests that topical diphenylcyclopropenone (DPCP) may be beneficial for treating both alopecia areata and verruca vulgaris, although it is not typically a first-line therapy.

Clascoterone safely promotes hair growth similar to minoxidil.